IL17A and Bone marrow hypocellularity: Suppression of the expansion of Th17 cells by treatment with an anti-IL-17 antibody could increase the proportion of Treg cells in a murine model of immune-mediated bone marrow failure, downregulate the production of IFN-γ levels, and reduce the severity of bone marrow failure [29].